Genetics of Mast Cell Activation Syndrome
Mast cell activation syndrome involves recurrent, inappropriate mast cell degranulation causing multisystem symptoms. Overlapping with the mcas condition entry, this provides the formal syndrome-level view with clinical context and diagnostic framework.
This page is for educational and informational purposes only. Not a diagnostic tool. Always consult a qualified healthcare provider.
What is Mast Cell Activation Syndrome?
Mast cells are tissue-resident immune cells that degranulate rapidly in response to immune signals, releasing histamine, tryptase, prostaglandins, leukotrienes, and cytokines. Mast Cell Activation Syndrome (MCAS) is characterised by recurrent episodes of mast cell mediator release without evidence of neoplastic mast cell proliferation. It can be primary (clonal), secondary (driven by IgE or other stimuli), or idiopathic. MCAS prevalence appears substantially increased in Long COVID, likely reflecting immune dysregulation and possibly autoantibodies against mast cell-activating receptors. The co-occurrence of MCAS with POTS and hypermobile EDS — the 'trifecta' — is well-recognised.
Biological pathways commonly discussed in relation to Mast Cell Activation Syndrome
Research into Mast Cell Activation Syndrome and Mast Cell Biology has highlighted several biological pathways that may be relevant. Genetic variants within these pathways may influence individual susceptibility, symptom severity, or the trajectory of the condition.
Mast Cell Activation Signalling
KIT (CD117) and FcεRI are the primary mast cell activation receptors. Activating KIT mutations cause mastocytosis. Variants affecting KIT or FcεRI sensitivity may lower mast cell activation thresholds.
Mediator Release
Mast cell degranulation releases pre-formed mediators (histamine, tryptase, heparin) and triggers synthesis of new mediators (PGD2, LTC4, TNF). TPSAB1 copy number variants affect tryptase levels.
Mast Cell Histamine
Histamine is the most abundant preformed mast cell mediator. Its effects on H1-H4 receptors drive allergic, cardiovascular, and neurological symptoms. Degradation by DAO and HNMT determines histamine clearance rate.
Mast Cell Immune
Mast cells interact with T cells, IgE-producing B cells, and innate immune cells. IL-33 and TSLP are epithelial alarmins that activate mast cells during stress or injury.
Key genes studied in relation to Mast Cell Activation Syndrome
The following genes have been studied in relation to Mast Cell Activation Syndrome and Mast Cell Biology. These genes span the biological pathways most commonly discussed in this area of research.
19 genes total studied in relation to Mast Cell Activation Syndrome across the ChronicDNA dataset.
Genetic variants commonly discussed
The following genetic variants (SNPs) are found in genes that have been studied in relation to Mast Cell Activation Syndrome. Each variant represents a position in the genome where individuals may carry different alleles.
59 variants total across genes studied in relation to Mast Cell Activation Syndrome.
How personal DNA data may provide educational insights
Consumer DNA files from 23andMe, AncestryDNA, and MyHeritage contain raw SNP data. When you upload your file to ChronicDNA, the analysis engine checks your genotype against a curated panel of 80+ genes selected for their relevance to Long COVID, ME/CFS, and connected biological pathways - some of which may relate to areas such as Mast Cell Activation Syndrome.
This is not a diagnostic service. Genetic variants do not determine whether you have Mast Cell Activation Syndrome, nor do they predict your clinical outcomes. The report is educational - it explains which variants you carry, what the research says about them, and how they fit into the biological pathways most relevant to chronic illness. All results should be discussed with a qualified healthcare provider.
Related conditions and pathways
Mast Cell Activation Syndrome shares biological pathways and genetic associations with the following related conditions and areas of research.
Frequently asked questions
What is Mast Cell Activation Syndrome?
MCAS is a disorder involving inappropriate or excessive mast cell activation, causing recurrent multisystem symptoms including flushing, urticaria, angioedema, gastrointestinal distress, and cardiovascular instability. It is diagnosed by elevated mast cell mediators (particularly tryptase) during episodes.
How common is MCAS in Long COVID?
MCAS appears significantly over-represented in Long COVID — some estimates suggest 30–40% of Long COVID patients may meet MCAS criteria. Post-COVID mast cell hyperactivation may be triggered by viral immune disruption, autoantibodies against mast cell receptors, or persistent low-grade inflammation.
What is TPSAB1 and how does it relate to MCAS?
TPSAB1 encodes alpha-tryptase, a mast cell mediator. Duplications of the TPSAB1 gene increase baseline tryptase levels — a condition called hereditary alpha-tryptasemia (HαT), which is associated with elevated risk of MCAS symptoms and hypersensitivity reactions. HαT is present in approximately 4-6% of the general population.
What are the genetic connections between MCAS, POTS, and hypermobile EDS?
The 'trifecta' of MCAS, POTS, and hEDS co-occurs far more frequently than chance. Proposed connections include connective tissue fragility affecting mast cell stability, autonomic dysregulation amplifying mast cell activation, and shared genetic predispositions — though specific shared causal variants have not been definitively identified.
Explore DNA insights
If you already have DNA data from 23andMe, AncestryDNA, or MyHeritage, upload your raw file to ChronicDNA and receive a personalised educational report covering genes studied in relation to Mast Cell Activation Syndrome and connected biological pathways.
Get Your Personalised DNA ReportInformational and educational only · Not a diagnostic tool · GDPR compliant
19 genes · 59 variants analysed in relation to Mast Cell Activation Syndrome